Retatrutide

Retatrutide Peptide

Retatrutide is an experimental peptide being studied in scientific studies as triple agonist of the GLP-1, GIP and glucagon receptors. Research focuses on mechanisms surrounding body weight, energy balance and metabolic regulation. It  is only intended for research purposes.

FIT PEPTIDES  is a research-grade product for professional laboratory research, such as in vitro studies, analytical testing and method development.

It is an investigational medication developed for obesity and type 2 diabetes. Unlike current GLP-1 drugs, it activates three different hormone receptors, which is why it’s often called a triple agonist.

It targets:

• GLP-1 receptor – reduces appetite, slows stomach emptying, and improves blood sugar.
• GIP receptor – enhances insulin release and may improve how the body handles fat.
• Glucagon receptor – increases energy expenditure (burning more calories) and may promote fat loss.